Paul Hastings Advises the Underwriters in Humacyte’s Common Stock Offering

Paul Hastings LLP advised TD Cowen, Barclays and BTIG as joint book-running managers and H.C. Wainwright & Co. and The Benchmark Company as lead managers for Humacyte, Inc.’s (Nasdaq: HUMA) offering of 25,000,000 shares of common stock. The offering is expected to close on or about March 27, 2025, subject to customary closing conditions.

Co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which also included associates Chris Guerin and Adam Swank.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.